🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are escalating worldwide, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are seen in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

According to data published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which uses a dual-drug approach. The research involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Doctors on the front lines have shared hope. Access to a one-pill regimen such as this is seen as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea globally.